AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00739596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks
Description: Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
Study NCT00739596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine: 8 weeks
Description: Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
Study NCT03813823 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fear tasks
Description: All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
Study NCT03894904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue papaverine, as needed
Description: If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
Study NCT03894904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue papaverine, as needed
Description: If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
Study NCT03080922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell
Description: high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
Study NCT02349477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a pill that looks exactly like the active medication but does not contain medication
Study NCT02241772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Study NCT02241772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03484195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
Study NCT01866735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Rehabilitation Therapy
Study NCT02527083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02527083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study NCT02527083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT02581527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
Study NCT02527083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Study NCT03584386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-CAMS (aka Jaspr)
Description: V-CAMS is an integrated software system for use on any device by suicidal patients.
Study NCT02813512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADSCs
Description: Autologous ADSCs
Study NCT02844712 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of reexposure to a negatively tested betalactam
Study NCT00987935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: 400 mg twice daily
Study NCT00987935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Twice daily
Study NCT00667979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
Study NCT00667979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03352180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic reapir of subscapularis tendon
Description: arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
Study NCT03352180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopic debridement of subscapularis tendon
Description: arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
Study NCT01326897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Homes/Healthy Families
Description: Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings.
Study NCT01326897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
Study NCT03981198 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Soliton Rapid Acoustic Pulse (RAP)
Description: Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
Study NCT03931512 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimularion
Description: aplication of direct current stimulation on the scalp wiht sponge electrodes
Study NCT03931512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimularion
Description: aplication of direct current stimulation on the scalp wiht sponge electrodes
Study NCT02349828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Study NCT00007774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Study NCT00007774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study NCT00345592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual (atrial and ventricular) implantable defibrillator
Description: The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
Study NCT00345592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual (atrial and ventricular) implantable defibrillator
Description: In hospital application of anti arrhythmic therapies via the device
Study NCT00345592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual (atrial and ventricular) implantable defibrillator
Description: Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
Study NCT00551993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic laparoscopic sacrocolpopexy
Description: Da Vinci Robot
Study NCT00551993 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Sacral Colpopexy
Description: Standard laparoscopy
Study NCT02275533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT02275533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT02275533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT02275533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT02275533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo standard of care clinical observation
Study NCT02275533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02275533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02275533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04305652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Progressively Lowered Stress Threshold Model
Description: PLST is a conceptual model for reducing behavioral symptoms in individuals with dementia. The PLST model provides the foundation for a psychoeducational intervention that assists formal and informal caregivers in understanding behaviors and planning care for individuals with dementia. If the model is to be applied at home, at least three home visits are made in line with the listed principles. While making a diagnosis during the first home visit, a maintenance plan for the problems is created in other home visits and the caregiver is trained to implement the care plan. After the home visits, the process is carried out by providing counseling through telephone calls or face-to-face interviews when necessary.
Study NCT01284738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiopathology
Description: Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units.
Study NCT01284738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiopathology
Description: Three sequential biological evaluations will be performed for each patient and will consist in :~* the dosages of MP carried out by the UMR 608 in Marseille,~* the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.
Study NCT02581527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid 75mg - all arms
Study NCT02581527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 75mg - all arms
Study NCT02581527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Ethambutol 275mg - all arms
Study NCT02581527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Ethambutol 275mg - all arms
Study NCT02581527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide 400mg - all arms
Study NCT02581527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide 400mg - all arms
Study NCT04508205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGB-400
Description: BID application
Study NCT03062410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic PRO in daily clinical practice
Description: All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
Study NCT06298162 — intervention group
Intervention type: OTHER
Intervention: 2 years after RYGB, no intervention. MRI measurement. Observational.
Description: no intervention. MRI measurement. Observation.
Study NCT03845049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inclusion examinations
Description: Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
Study NCT03845049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion examinations
Description: Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
Study NCT03051776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Study NCT03051776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Garment
Study NCT00458822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00458822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT01444196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Desloratadine
Description: Every day,per mouth,in the evening, for 14 +- 2 days.
Study NCT02331108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selection of anesthetic induction technique
Description: Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
Study NCT02763488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DelfiPTS tourniquet system
Study NCT02763488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Study NCT01774058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilomedin
Description: 3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
Study NCT01476969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning
Description: the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
Study NCT04163094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W_ova1 Vaccine
Description: Patients will be treated with a W_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
Study NCT03288584 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab (Actemra®)
Description: Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
Study NCT01828112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib is the investigational treatment and is referred to as the investigational study drug and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
Study NCT01828112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m2 every 21 days.
Study NCT01828112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m2 every 21 days.
Study NCT04010227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
Study NCT04010227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education/Support
Description: Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
Study NCT02082327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV migalastat HCl
Study NCT02082327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo
Study NCT02082327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral migalastat HCl
Study NCT03196817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%
Description: 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
Study NCT03196817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wrist splinting
Description: Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
Study NCT03416049 — intervention group
Intervention type: DEVICE
Intervention: PEMF therapy with a high-power PEMF device
Description: The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
Study NCT03416049 — intervention group
Intervention type: DEVICE
Intervention: PEMF therapy with a medium PEMF power device
Description: The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
Study NCT03416049 — intervention group
Intervention type: DEVICE
Intervention: PEMF therapy with a low-power PEMF device
Description: The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
Study NCT03416049 — intervention group
Intervention type: DEVICE
Intervention: PEMF therapy with the sham PEMF device
Description: The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
Study NCT03920449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxins
Description: In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
Study NCT03920449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral internal sphincterotomy
Description: In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
Study NCT02226653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT00544726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Study NCT00544726 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No training
Study NCT01897324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin, Novo nordisk)
Study NCT01824498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat diet
Description: Low fat diet = 20% fat
Study NCT01824498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fat high n3 diet
Description: Low Fat high n3 diet = 20% fat + 3% n3
Study NCT01824498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: High Fat Diet = 40% fat
Study NCT00850551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Intervention
Description: Twice a week home spirometry and symptom assessment
Study NCT00850551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Intervention
Description: Twice a week home spirometry and symptom assessment
Study NCT01072162 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eltrombopag
Description: 25 mg tablet
Study NCT01072162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 25 mg powder for oral suspension